NATICK, Mass., Sept. 25 /PRNewswire/ — Boston Scientific
Corporation (NYSE:
BSX) today announced three-year follow-up data from the
HORIZONS-AMI trial. The trial, sponsored by the
Cardiovascular Research Foundation (CRF) with grant support from
Boston Scientific and The Medicines Company (Nasdaq:
MDCO), is designed to determine the safety and efficacy of the
TAXUS® Express2™ Paclitaxel-Eluting Coronary Stent System
compared to bare-metal stenting in patients experiencing an acute
myocardial infarction (AMI), or heart attack. With 3,006
patients enrolled worldwide, HORIZONS-AMI is the largest randomized
trial to compare the use of drug-eluting stents to bare-metal
stents for AMI patients. Analysis of the data was presented
by Gregg W. Stone, M.D., Professor of Medicine and the Director of
Research and Education at the Center for Interventional Vascular
Therapy at the Columbia University Medical Center/New
York-Presbyterian Hospital and Principal Investigator of the trial,
at CRF’s annual Transcatheter Cardiovascular Therapeutics
scientific symposium in Washington, D.C.
“Follow-up data from the HORIZONS-AMI trial continue to show
that, in patients with AMI, paclitaxel-eluting stents were superior
in efficacy to bare-metal stents and had a comparable safety
profile,” said Dr. Stone. “Significant reductions in measures
of re-intervention at three years were observed with no evidence of
late catch-up.”
HORIZONS-AMI demonstrated that the TAXUS Express Stent
significantly reduced clinical and angiographic restenosis compared
to an otherwise identical bare-metal Express® control stent.
After three years follow-up, the primary efficacy endpoint of
ischemia-driven target lesion revascularization (TLR) was 9.4
percent for patients treated with TAX
‘/>”/>
SOURCE